Carbidopa hydrochloride  (Synonyms: (S)-(-)-Carbidopa hydrochloride)

Carbidopa hydrochloride ((S)-(-)-Carbidopa hydrochloride) is a drug used to inhibit Parkinson's disease, which has the activity of inhibiting the peripheral metabolism of levodopa. Carbidopa hydrochloride can increase the proportion of peripheral levodopa penetrating the blood-brain barrier, thereby enhancing its effect on the central nervous system. Carbidopa hydrochloride has also been found to be an aryl hydrocarbon receptor (AhR) ligand with anticancer activity, which can inhibit the growth of pancreatic cancer cells and tumors. The selective AhR regulation properties of carbidopa hydrochloride provide potential prospects for its clinical application^[1].

262.69

C₁₀H₁₅ClN₂O₄

65132-60-7

OC(C=C1C[C@@](NN)(C)C(O)=O)=C(C=C1)O.Cl

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Carbidopa: a selective Ah receptor modulator (SAhRM)  [Content Brief]

  [2]. Safe S. Carbidopa: a selective Ah receptor modulator (SAhRM). Biochem J. 2017;474(22):3763-3765. Published 2017 Nov 6.  [Content Brief]

  [3]. Fermaglich J. Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa. Med Ann Dist Columbia. 1974;43(12):587-591.  [Content Brief]